News Vertex is smarting from a pain portfolio setback Shares in Vertex Pharma have come under pressure after one of its non-opioid pain candidates failed to move the needle in a mid-stage trial.
News Vertex bags FDA okay for its non-opioid pain drug Vertex gets FDA approval for its non-opioid pain drug suzetrigine, the first new class of pain medicine in the US in more than 20 years.
News Tris cues up filing for non-opioid pain drug on phase 3 win Tris Pharma has set its sights on an FDA filing for non-opioid pain drug cebranopadol this year after hitting the mark in an abdominoplasty trial.
News Tenax trounced by phase 3 heart failure readout Shares in Tenax 85% of their value after its drug for patients with pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.